Invasive Fungal Infection Market Size, Share, Growth, Trends, and Global Industry Analysis: By Disease Type (Candidemia and Invasive Candidiasis, Intra-Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, and Others), By Drug Type (Polyenes, Triazoles, Echinocandins, Flucytosine, and Others), By Distribution Channel (Retail Pharmacies, Hospital, and E-Commerce), and Region

Invasive Fungal Infection Market Size was valued at US$ 10,245 million in 2023 and is projected to reach US$ 13,447 million by 2030, and poised to grow at a 3.3% CAGR from 2024 to 2030. Invasive Fungal Infection caused by a yeast called Candida. It occurs in the mouth and throat, or vaginal “yeast Infection” affects blood, heart, brain, eyes, bones, and other parts of the body. the rising incidence of invasive fungal infections due to the increased number of immunocompromised patients, the growing prevalence of chronic diseases escalate the market growth.The rising population of fungal infection patients, according to the American Society of Microbiology, Invasive Fungal infection is responsible for killing 1.5 million people per year consequence of the high demand for treatment for such infections which drives the growth of the market.

In the past years, it is observed that rising healthcare infrastructure and research and development activities by the key players also extensive spending for the treatment have led to lucrative opportunities in the market. The adverse reaction of many fungal infections, patients facing immunosuppressive reactions which hinder the market growth of the invasive fungal infection market. The rise in function infection diseases such as candidiasis, intra-abdominal candidiasis, and others covering the fungal infection market, affects in mouth, throat, and blood, and consequences rise in the treatment market which is the ongoing trend in the market.  

Invasive Fungal Infection Market Key Developments:

• In March 2023, the FDA approved Cidara’s antifungal REZZAYO for Candidiasis. Rezzayo is a next-generation echinocandin and the first new treatment option in the indication in more than a decade. Unlike typical yeast infections, candidiasis can affect the blood, eyes, heart, brain and bones, according to the CDC.
• In April 2021, Pfizer Inc. announced to acquire Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.